138 days ago • Posted by William Ramstein

Artelo Biosciences Inc. shares rose 8% to $2.11

Artelo said it got accepted into the first round of the Alderley Park Oncology Development Program, a U.K. national program designed to offer advice, guidance, and financial support to develop and progress innovative oncology projects. The biopharmaceutical company said the program is funded by Innovate UK and Cancer Research UK and supported by major oncology-focused pharmaceutical companies including AstraZeneca, Johnson & Johnson, GlaxoSmithKline and Roche.

Source: Dow Jones

bg_nwsletter